Sterling Pharma Solutions

Sterling Pharma Solutions is a leading Contract Development and Manufacturing Organisation (CDMO) specializing in Active Pharmaceutical Ingredient (API) and Antibody-Drug Conjugate (ADC) services. With a legacy spanning over 50 years, the company offers comprehensive support across the entire molecule lifecycle, from early-stage discovery through to commercial manufacturing. Their expertise is crucial for pharmaceutical and biotech firms seeking to advance novel therapeutics. Sterling Pharma Solutions leverages deep scientific knowledge and advanced manufacturing capabilities to serve a global client base.

Operating from state-of-the-art facilities located in the UK and the US, Sterling Pharma Solutions is equipped to handle complex and hazardous chemistry, including high potency APIs and peptide manufacturing. The company's operational footprint supports a wide array of services designed to accelerate drug development timelines. Their commitment to scientific collaboration and innovation ensures clients receive efficient and cost-effective pathways to market. Meet Sterling Pharma Solutions's team to understand the expertise driving their success. The company employs between 1,000-5,000 individuals across its locations.

Sterling Pharma Solutions's product portfolio encompasses pharmaceutical development, contract manufacturing, and GMP-compliant services, positioning them as a key partner in the healthcare ecosystem. Their strategic focus on quality and scientific rigor enables the development of innovative solutions for challenging pharmaceutical projects. The company's revenue stands at $455.7M, reflecting its significant market presence and operational scale within the competitive CDMO landscape. Their B2B focus targets clients requiring specialized API and ADC development and manufacturing.